Session Information

Sponsored Seminar

[ILS-FR-19] Lunch Seminar 19: EVIDENCE OF NEUROPROTECTION IN TOPICAL TREATMENT
Go back
print
Day
Apr 04 (Fri)
Time
12:15 - 13:15
Room
Room 4 - Tokyo International Forum 7F Hall B7 (2)
Sponsor
SENJU PHARMACEUTICAL CO.,LTD. / ALLERGAN, INC.
Topic
Glaucoma
Chair/Coordinator
Chair)Makoto Araie、Chair)Robert Weinreb
Description
Approaches to neuroprotection include identifying exogenous agents that alleviate neuronal damage or upregulate causative intracellular processes. Several topical anti-glaucoma agents reportedly show neuroprotective effects in vitro, particularly brimonidine that is neuroprotective in several experimental systems. Moreover, topical brimonidine 0.2% better preserved visual field than timolol 0.5% in the randomized double masked Low-pressure Glaucoma Treatment Study (LoGTS). In this symposium, the pathophysiology of optic nerve damage and its amelioration via neuroprotection, particularly with brimonidine, will be addressed.

ILS-FR-19 / 

Glaucoma

Basic Science of Neuroprotection

Hidenobu Tanihara

Basic Science of Neuroprotection

ILS-FR-19 / 

Glaucoma

A Review of Clinical Studies of Neuroprotection

David Greenfield

A Review of Clinical Studies of Neuroprotection

ILS-FR-19 / 

Glaucoma

Clinical Experience with Brimonidine

Ki-Ho Park

Clinical Experience with Brimonidine

Go back